1

Supplementary Online Content

- 2 Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Dexamethasone 12 mg versus 6 mg
- 3 for patients with COVID-19 and severe hypoxia: an international, randomized, blinded trial
- 4
- 5 **eFigure 1.** Masking of Trial Medication
- 6 **eFigure 2.** Number of Enrolments per Site
- 7 **eFigure 3.** Number of Enrolments per Month
- 8 **eFigure 4.** Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary
- 9 Outcome Assigning Patients Who Had Died at Day 28 the Worst Possible Outcome (i.e., 0
- 10 Days Alive Without Life Support)
- eTables 1a and 1b. Randomizations in Error and Wrongly Entered Stratification Variables
- 12 **eTable 2.** Trial Medication Administration and Protocol Violations
- eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol Population
- eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome
- eTable 5. Post Hoc Analyses of the Primary Outcome Assigning Patients Who had Died at
- 16 Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)
- 17 **eTable 6.** Analyses of the Single Components of Composite Outcomes
- **eTable 7.** Results of the Unadjusted Analyses of Secondary Outcomes
- 19 **eTable 8.** All Serious Adverse Reactions and Serious Adverse Events
- eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of Randomization
- eTable 10. Discharge Against Medical Advice within 28 Days of Randomization

22 Contents

23	List of eFigures	3
24	List of eTables	4
25	eMethods	5
26	The COVID STEROID 2 Trial Group	5
27	Acknowledgements	11
28	Inclusion Criteria	12
29	Exclusion Criteria	13
30	Baseline Characteristics	14
31	Outcome definitions	17
32	Criteria for Discontinuation of Trial Medication and Withdrawal	20
33	Trial Populations	21
34	Handling of Missing Data	22
35	Abstract Written before Breaking the Randomization Code	24
36	eFigures	25
37	eTables	30
38	eReferences	40

40 List of eFigures

41		
42	eFigure 1. Masking of Trial Medication	25
43	eFigure 2. Number of Enrolments per Site	27
44	eFigure 3. Number of Enrolments per Month	28
45	eFigure 4. Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary Outcom	e
46	Assigning Patients Who had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive	
47	Without Life Support)	29

48 List of eTables

50	eTable 1a and 1b. Randomizations in Error and Wrongly Entered Stratification Variables	30
51	eTable 2. Trial Medication Administration and Protocol Violations	31
52	eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol Population*	32
53	eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome	33
54	eTable 5. Post Hoc Analyses of the Primary Outcome Assigning Patients Who had Died at Day 2	28
55	the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)	34
56	eTable 6. Analyses of the Single Components of Composite Outcomes	35
57	eTable 7. Results of the Unadjusted Analyses of Secondary Outcomes	36
58	eTable 8. All Serious Adverse Reactions and Serious Adverse Events*	37
59	eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of Randomization*	38
60	eTable 10. Discharge Against Medical Advice within 28 Days of Randomization*	39

- 62 **eMethods**
- 63

64 The COVID STEROID 2 Trial Group

65

66 Management Committee

- 67 Anders Perner (Sponsor and Chair of Management Committee), Marie Warrer Munch
- 68 (International Coordinating Investigator), Maj-Brit Nørregaard Kjær (International Project Manager),
- 69 Anders Granholm (National investigator Denmark), Morten Hylander Møller (National investigator
- Denmark), Tine Sylvest Meyhoff (National investigator Denmark), Gitte Kingo Vesterlund
- 71 (National Project Manager Denmark), Marie Helleberg (National investigator Denmark), Thomas
- 72 Benfield (National investigator Denmark), Balasubramanian Venkatesh (Co-chair), Naomi
- 73 Hammond (Senior Research Fellow and Operations Lead Australia), Sharon Micallef (Project
- 74 Manager Australia), Vivekanand Jha (Co-chair), Bharath Kumar Tirupakuzhi Vijayaraghavan
- 75 (National Investigator India), Sheila Nainan Myatra (National Coordinating Investigator India),
- 76 Maria Cronhjort (National Investigator Sweden), Rebecka Rubenson Wahlin (National
- 77 Coordinating Investigator Sweden), Stephan Jakob (National Investigator Switzerland), Luca
- 78 Cioccari (National Coordinating Investigator Switzerland), Christian Gluud (Trialist), and Theis
- 79 Lange (Statistician).
- 80

81 Management Committee for the Indian Sites

Balasubramanian Venkatesh (Co-chair), Vivekanand Jha (Co-chair), Sheila Nainan Myatra 82 83 (National Coordinating Investigator), Naomi Hammond (Senior Research Fellow and Operations Lead - Australia), Abhinav Bassi (Project Manager - India), Sharon Micallef (Project Manager -84 Australia), Anubhuti Jha (Site Coordinator – India), Mallikarjuna Kunigari (Program Manager – 85 India), Bharath Kumar Tirupakuzhi Vijayaraghavan (National Investigator), Oommen John (Senior 86 87 Research Fellow – India), Ashwani Kumar (Research Associate – Australia and India), Anders 88 Perner (Sponsor), Marie Warrer Munch (International Coordinating Investigator), Maj-Brit 89 Nørregaard Kjær (International Project Manager).

- 90
- 91
- 92

93	Regional Coordinating Centre for India
94	The George Institute for Global Health, Sydney, Australia: Naomi Hammond, Ashwani Kumar,
95	Sharon Micallef, Dorrilyn Rajbhandari, Balasubramanian Venkatesh
96	
97	Local Coordinating Centre for India
98 99	The George Institute for Global Health, New Delhi, India: Sumaiya Arfin, Abhinav Bassi, Nikita Bathla, Anubhuti Jha, Vivekanand Jha, Oommen John, Rajesh Joshi, Mallikarjuna Kunigari.
100	
101	Independent Data Monitoring and Safety Committee
102	Christian Hassager (Clinician), Manu Shankar-Hari (Trialist), and Susanne Rosthøj (Statistician).
103	
104	Site investigators and research staff
105	The primary investigator at each site is marked with *.
106	
107	Denmark
108	Department of Intensive Care, Copenhagen University Hospital – Rigshospitalet: Marie Warrer
109	Munch*, Anders Perner, Maj-Brit Nørregaard Kjær, Morten Hylander Møller, Anders Granholm,
110	Gitte Kingo Vesterlund, Tine Sylvest Meyhoff, Lene Russell, Kis Rønn Uhre, Ann Louise Syrach
111	Lindgaard, Jette Degn, Mik Wetterslev, Praleene Sivapalan, Carl Thomas Anthon, Vibe Sommer
112	Mikkelsen, Louise Colette la Porte, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
113	Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
114	Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
115	Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.
116	Department of Infectious Diseases, Copenhagen University Hospital – Rigshospitalet: Marie
117	Warrer Munch*, Marie Helleberg, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
118	Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
119	Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
120	Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.

- 121 Department of Thoracic Anaesthesiology, Copenhagen University Hospital Rigshospitalet: Marie
- 122 Warrer Munch*, Vibeke Lind Jørgensen, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla
- Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl
- Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv
- 125 Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias
- 126 Saxtorph Aksnes.
- 127 Department of Neuroanaesthesiology, Copenhagen University Hospital Rigshospitalet: Marie
- 128 Warrer Munch*, Margit Smitt, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno
- 129 Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan
- 130 Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard
- 131 Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.
- 132 Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region,
- 133 Copenhagen University Hospital Rigshospitalet: Christian Gluud*, Janus Engstrøm.
- 134 Department of Infectious Diseases, Copenhagen University Hospital Amager and Hvidovre:
- 135 Thomas Benfield*, Charlotte Kastberg Levin, Gitte Kronborg, Rikke Krogh-Madsen, Marie Qvist
- 136 Jensen, Jens Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen, Esben
- 137 Christensen Clapp, Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-Clausen,
- 138 Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen,
- 139 Emma Victoria Hatley, Tobias Saxtorph Aksnes.
- 140 Department of Intensive Care, Copenhagen University Hospital Amager and Hvidovre: Thomas
- 141 Benfield*, Klaus Tjelle Kristiansen, Ronni Thermann Reitz Plovsing, Marie Qvist Jensen, Jens
- 142 Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp,
- 143 Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi,
- 144 Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria
- 145 Hatley, Tobias Saxtorph Aksnes.
- 146 Department of Respiratory Medicine, Copenhagen University Hospital Amager and Hvidovre:
- 147 Thomas Benfield*, Charlotte Suppli Ulrik, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla
- 148 Meno Kristensen, Trine Bak Jonassen, Esben Christensen Clapp, Thomas Steen Jensen, Carl
- 149 Johan Steensen Hjortsø, Matias Metcalf-Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv
- 150 Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-Andersen, Emma Victoria Hatley, Tobias
- 151 Saxtorph Aksnes.
- 152 Department of Anaesthesia and Intensive Care, Herlev Hospital: Anne Sofie Andreasen*, Helene
- 153 Brix, Marie Qvist Jensen, Jens Wolfgang Leistner, Camilla Meno Kristensen, Trine Bak Jonassen,

- 154 Esben Christensen Clapp, Thomas Steen Jensen, Carl Johan Steensen Hjortsø, Matias Metcalf-
- 155 Clausen, Reem Zaabalawi, Emilie Rose Bak, Liv Sanggaard Halstad, Suhayb Abdi, Emil Gleipner-
- 156 Andersen, Emma Victoria Hatley, Tobias Saxtorph Aksnes.
- 157 Department of Anaesthesia and Intensive Care, Copenhagen University Hospital, North Zealand:
- 158 Morten H. Bestle*, Martin Schønemann-Lund, Lone Valbjørn, Sanne Lauritzen, Ellen Bjerre Koch,
- 159 Valdemar Oskar Ingemann Sørensen, Hans Eric Sebastian Seitz-Rasmussen, Frederik Heiberg
- 160 Bestle.
- 161 Department of Anaesthesiology, Zealand University Hospital, Køge: Lone Musaeus Poulsen*, Nina
- 162 Christine Andersen-Ranberg, Camilla Bekker Mortensen, Cecilie Bauer Derby, Kirstine Nanna la
- 163 Cour, Sarah Weihe, Alison Holten Pind, Emma Ritsmer Stormholt.
- Department of Anesthesia and Intensive Care, Slagelse Hospital, Slagelse: Anders Møller*, Klaus
 Vennick Marcussen*, Yifei Cao.
- 166 Dept. of Anaesthesia and Intensive Care, Odense University Hospital: Thomas Strøm*, Jens
- Michelsen, Eva Lærkner, Christine Gilberg, Michella Poulsen, Hanne Tanghus Olsen, CharlotteRosenkilde.
- Department of Anaesthesia and Intensive Care, Kolding Hospital: Anne Craveiro Brøchner*, TrineHaberlandt.
- Department of Regional Health Research, Faculty of Health Sciences, University of SouthernDenmark: Christian Gluud*.
- 173 Dept. of Anaesthesiology and Intensive Care, Bispebjerg and Frederiksberg Hospital: Christian
- Aage Wamberg*, Lars Peter Kloster Andersen, Diana Bertelsen Jensen, Mia Charlotte Krogh
- 175 Hansen.
- Department of Anaesthesia, Herning Hospital: Iben Strøm Darfelt*, Nilanjan Dey, Lene FriholdtMahler.
- 178 Department of Anaesthesia and Intensive Care, Aalborg University Hospital: Bodil Steen
- 179 Rasmussen*, Olav Lilleholt Schjørring, Søren Rosborg Aagaard, Stine Rom Vestergaard, Anne-
- 180 Marie Gellert Bunzel, Rine Moulvad Siegumfeldt, Thomas Lass Klitgaard, Kirsten Uldal Krejberg.
- 181 Department of Infectious Diseases, Aalborg University Hospital: Bodil Steen Rasmussen*, Henrik182 Nielsen.
- 183

184 <u>India</u>

Department of Critical Care Medicine, Apollo Main Hospital, Chennai: Bharath Kumar Tirupakuzhi
Vijayaraghavan*, Ajay Padmanaban*, Evangeline Elvira, Hilda Nirmala Kumari, Jayanthi
Swaminathan, Arun Chander K, Ganesh Rajan N, Sona Thomas, Ann Thomas, Vishnu
Odankadummal, Anu M Antony.

Department of Anaesthesia, Critical Care and Pain, Tata Memorial Hospital, Mumbai: Sheila
Nainan Myatra*, Jigeeshu V. Divatia*, Atul P Kulkarni, Nishanth Baliga, Nirmalyo Lodh, Swapna C
Vijayakumaran, Tarun Sahu, Kushal Kalvit, Vijaya P Patil, Amol T Kothekar, Shilpushp J Bhosale,
Manoj Gorade, Anjana M Shrivastava.

Department of Intensive Care. P.D. Hinduja National Hospital & Medical Research Centre: Farhad
N. Kapadia*. Jare Jagannath Uddhavrao, Ritika Sharma, Jyotsna Mali, Niranjan H R, Celine Lobo,
Vaishali Neve, Deepika Maurya, Mahesh Salunke, Santiswaroop Pattanaik, Akhilesh Agrawal,
Ashit Hegde, Rishi Kumar Badgurjar.

Department of Critical Care Medicine, Bombay Hospital Institute of Medical Sciences: Pravin R
Amin*, Binit N Jhaveri, Digamber B Sarje, Ananda HJ, Bitan Sen, Ambily CM, Emilin P Jose.

Intensive Care Unit, S.L. Raheja Fortis Hospital, Mumbai: Sanjith Saseedharan*, Vaijayanti
Kadam, Annapurna Chiluka, Rohit Kuril, Elizabeth Mathew, Suvarna Shirsekar.

Department of Respiratory Medicine, Indraprastha Apollo Hospital, New Delhi: Rajesh Chawla*,
Sudha Kansal, Rinku Dahiya, Vijay Kumar Thakur, Rajni Tewatia, Savita Rawat, Harsh Tyagi.

- Intensive Care Unit, Symbiosis University Hospital and Research Centre, Pune: Urvi Shukla*,
 Meenakshi Bhakare, Chinmayee Bhise, Amit Girme, Lini T. Kunjumon, Merlin Jose, Nikunj
 Sharma, Amol Bali.
- Department of Critical Care Medicine, Sir HN Reliance Foundation Hospital: Mehul Shah*, Mayur
 Patel, Nirankar Bhutaka, Edwin Pathrose, Gopal Goyal, Riya Baby, Roshini Fernandez.
- Department of Critical Care Medicine, Rajendra Institute of Medical Sciences: Mohd Saif Khan*,
 Pradip K Bhattacharya, Srishti Kindo, Aaditya A, Kritika Raj, Aastha Poddar, Aftab Ansari,
 Mustaque Alam.
- 211 Department of Internal Medicine, Vishwaraj Hospital, Pune: Kapil Borawake*, Vijay Khandagale,
- 212 Satish Sarode, Sanesh Garde, Sushant Shinde ,Namdev Jagtap ,Chagan Khartode, Amit Palange,
- Aishwarya Pawar, Mayuri Mulay, Simrah Pirzade, Mohini Jagtap, Balbhim Rathod.

- Department of Anaesthesiology, Gujarat Medical Education & Research Society (GMERS) Medical
 College and General Hospital, Gotri: Neeta Bose*, Dhara Tanna, Kinjal Chaudhary.
- 216 Department of Medicine, Gujarat Medical Education & Research Society (GMERS) Medical
- 217 College and General Hospital, Gotri: Neeta Bose *, Shubhangi Deshpande, Rikin Raj.
- 218 Department of Critical Care, Sanjeevan Hospital: Subhal Dixit*, Sourab Ambapkar, Shobhana
- Ambapkar, Mukund Penurkar, Amit Sambare, Ravindra Joshi, Bhushan Kinolkar, Tarannum AslamShaikh.
- 221
- 222 <u>Sweden</u>
- 223 Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet: Rebecka
- Rubenson Wahlin*, Maria Cronhjort, Jacob Hollenberg, Anders Hedman, Anton Berggren, Felix
- 225 Alarcón, Gabriel Yamin, Adam Heymowski.
- 226 Department of Anaesthesia and Intensive Care, Södersjukhuset: Rebecka Rubenson Wahlin*,
- 227 Maria Cronhjort, Anton Berggren, Felix Alarcón, Gabriel Yamin, Adam Heymowski.
- 228 Department of Cardiology, Medical Intensive Care Unit, Södersjukhuset: Rebecka Rubenson
- 229 Wahlin*, Jacob Hollenberg, Anders Hedman, Anton Berggren, Felix Alarcón, Gabriel Yamin, Adam
- 230 Heymowski.
- 231 Department of Anaesthesia and Intensive Care, Universitetssjukhuset i Linköping: Michelle Chew*,
- Helen Didriksson, Carina Jönsson, Gunilla Gagnö.
- 233

234 <u>Switzerland</u>

- 235 Department of Intensive Care Medicine, Bern University Hospital (Inselspital): Luca Cioccari*,
- 236 Stephan Jakob, David Zacharias, Margaret Lynn Jong, Marianne Roth, Rachelle Mader, Laureta
- 237 Fazlija, Manuela Akaltan, Anja Eichenberger, Gion Rüegg, Tatjana Dill, Bruno Schoenmaekers.

238 Acknowledgements

- 239 We would like to thank all patients and relatives for agreeing to participate in the COVID STEROID
- 240 2 trial; all clinical and research staff at the participating hospitals; the regulatory authorities in the
- 241 participating countries for the expedite handling of the protocol; and the funding sources.
- 242 We would also like to thank all clinical and research staff involved in the design and conduct of the
- 243 'Low-dose hydrocortisone in patients with Covid-19 and severe hypoxia (COVID STEROID) trial'
- 244 which preceded the COVID STEROID 2 trial'.¹
- 245

.

247 Inclusion Criteria

- Adult patients (aged 18 years or above at the time of randomization)
- Confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requiring
 hospitalisation: we accepted any detections of SARS-CoV-2 approved by the local health
 authorities in the participating countries (i.e. pharyngeal swab, tracheal secretion or
 bronchoalveolar lavage).
- Use of either of the following:
- Invasive mechanical ventilation: use of mechanical ventilation via a cuffed endotracheal
 tube **OR**
- Non-invasive ventilation or continuous use of continuous positive airway pressure
- (CPAP) for hypoxia: Non-invasive ventilation includes positive pressure ventilation via a
 tight mask or helmet, continuous use of CPAP (via mask, helmet or tracheostomy, this
 does not include intermittent use of CPAP) **OR**
- Oxygen supplementation with an oxygen flow ≥10 L/min irrespective of system used
 (mask or nasal cannula) or the addition of atmospheric air.

262 Exclusion Criteria

Use of systemic corticosteroids for other indications than coronavirus disease 2019 (Covid-263 264 19) in doses higher than 6 mg dexamethasone equivalents: systemic corticosteroids (IV, IM, oral or per GI tube; not including nebulized, inhaled or transdermal corticosteroids) in 265 doses higher than 6 mg dexamethasone / 6 mg betamethasone / 200 mg cortisone / 160 266 mg hydrocortisone / 32 mg methylprednisolone / 40 mg prednisolone / 40 mg prednisone. 267 Other indications include adrenal insufficiency (i.e. primary, secondary or tertiary), anti-268 emetic treatment (i.e. post-operative or chemotherapy-induced nausea and vomiting), and 269 immunosuppressive treatment (i.e. rheumatic diseases, allergic diseases, chronic 270 obstructive pulmonary disease, haematological diseases, chronic kidney diseases, 271 272 autoimmune hepatitis, inflammatory bowel disease, chronic neurological diseases). Use of systemic corticosteroids for Covid-19 for 5 days or more: use of systemic 273 • corticosteroids for Covid-19 for 5 consecutive preceding days or more up to the day of 274 275 screening. 276 Invasive fungal infection: any of the following: 277 Suspected invasive fungal infection: presence of plasma markers in blood (e.g. -278 candida mannan antigen and galactomannan antigen). Confirmed invasive fungal infection: positive culture from blood, peritoneal fluid or 279 280 tissue. Active tuberculosis: either microbiologically confirmed or diagnosed based on 281 • 282 epidemiological, clinical and radiographic data. 283 • Pregnancy: confirmed by positive urine human gonadotropin (hCG) or plasma-hCG. A 284 negative urine or plasma-HCG test was mandatory for all women below 60 years of age. 285 • Known hypersensitivity to dexame has one: history of any hypersensitivity reaction to dexamethasone, including but not limited to urticaria, eczema, angioedema, bronchospasm 286 and anaphylaxis. 287 Previously randomized in the COVID STEROID 2 trial: patients who had previously been 288 • randomized in the COVID STEROID 2 trial, either during current or former hospitalisation. 289 290 Informed consent not obtainable: patients where the clinician or investigator was unable to • obtain the necessary consent according to the national regulations, including patients with 291 292 no relatives or patients who were hospitalized against their will.

Baseline Characteristics 293 Sex: the genotypic sex of the participant. 294 • Age at enrolment: the age of the participant in whole years at the time of randomization. 295 • 296 The age will be calculated from the date of birth and date of enrolment in the COVID STEROID 2 trial. 297 • Date of admission to hospital: the date of admission to the first hospital the participant was 298 299 admitted to during the current hospital admission. 300 • Number of days with symptoms of COVID-19 before hospital admission: the total number of days (as integer) with symptoms of COVID-19 before hospital admission. If the symptoms 301 302 started on the same day as hospital admission, the number of days with symptoms before hospital admission will be registered as 1. If the patient was infected while in hospital, the 303 number of days with symptoms before hospital admission will be registered as 0. 304 • Department at which participant was included: 305 306 Emergency department: accident/emergency/casualty/acute department at COVID STEROID 2 trial sites. 307 308 Hospital ward: medical or surgical ward at COVID STEROID 2 trial site, including 309 dedicated COVID-19 hospital wards. 310 Intermediate care unit: area of the hospital with higher resources to monitor patients as defined by the site, but invasive mechanical cannot be given. 311 Intensive care unit: area of the hospital where invasive mechanical can be given. 312 313 Other: any location in the same or another hospital not covered in the other 314 categories. Use of respiratory support at randomization: 315 Closed system (y/n): Use of invasive mechanical ventilation or non-invasive 316 ventilation or continuous use of continuous positive airway pressure (CPAP) for 317 318 hypoxia (defined in Supporting Information S2). If yes, latest FiO₂ prior to 319 randomization. 320 Open system with an oxygen flow ≥10 L/min: defined in Supporting Information S2. If yes, the maximum supplemental oxygen flow on an open system at randomization 321 (+/- 1 h) will be registered. 322 • Limitations of care (y/n): participant with limitation(s) in use of life support (i.e. invasive 323 mechanical ventilation, circulatory support, renal replacement therapy) and/or cardio-324 325 pulmonary resuscitation at the time of randomization.

326	٠	Chronic use of systemic corticosteroids for other indications than COVID-19 (y/n): systemic
327		corticosteroids (IV, IM, oral or per GI tube; not including nebulized, inhaled or transdermal
328		corticosteroids) for any other indications than COVID-19 at the time of randomization.
329	•	Treatment during current hospital admission prior to randomization:
330		- Agents with potential anti-viral action used against COVID-19: any treatment that
331		potentially inhibits viral replication, categorised as remdesivir, convalescent plasma,
332		or other (e.g. umifenovir, interferon alfa, interferon beta, camostat).
333		- Anti-bacterial agents: any antibiotic treatment commenced due to documented or
334		suspected bacterial infection before microbiological results are available.
335		- Agents with potential anti-inflammatory action: any treatment with potential anti-
336		inflammatory actions used against COVID-19 prior to screening, categorised as
337		Janus kinase inhibitor, IL-6 inhibitors or other.
338	•	Co-morbidities: any chronic co-morbidity present in the past medical history prior to
339		admission and defined as follows:
340		- History of ischemic heart disease or heart failure: previous myocardial infarction,
341		invasive intervention for coronary artery disease, stable or unstable angina, NYHA
342		class 3 or 4 or any measured left ventricular ejection fraction (LVEF) <40%.
343		- Diabetes mellitus: treatment at time of hospital admission with any anti-diabetic
344		medications.
345		- Chronic pulmonary disease: treatment at time of hospital admission with any
346		relevant drug indicating chronic pulmonary disease.
347		 Immunosuppressive therapy within the last 3-months: use of systemic
348		immunosuppressive drugs (e.g. tumor necrosis factor (TNF) inhibitors, calcineurin
349		inhibitors, mTOR inhibitors, anti-thymocyte globulins, interleukin-2 inhibitors,
350		mycophenolate, azathioprine, belimumab, corticosteroids), chemotherapy (e.g.
351		alkylating agents, anti-metabolites, mitotic inhibitors, topoisomerase inhibitors,
352		others) or radiotherapy within the last 3 months before randomization.
353	•	Blood values, interventions and vital parameters:
354		 Participant weight: measured or estimated in kilograms.
355		- PaO ₂ , SaO ₂ and lactate prior to inclusion: will be assessed from the most recent
356		arterial blood gas sample; alternatively, if arterial blood gas sample is not available,
357		SpO_2 will be assessed from the most recent measure by pulse oximeter.
358		- Circulatory support: infusion of any vasopressor/inotrope agent for a minimum of 1
359		hour (i.e. norepinephrine, epinephrine, phenylephrine, vasopressin analogues,

- angiotensin, dopamine, dobutamine, milrinone or levosimendan) within the last 24hours prior to randomization.
- Renal replacement therapy: any form of acute or chronic intermittent or continuous
 renal replacement therapy (including days between intermittent dialysis) within the
 last 72 hours prior to randomization.

366 Outcome definitions

367

368 **Primary outcome**

The days alive without life support at day 28 was calculated as the total number of days alive

- without any of the 3 life supporting interventions (listed below) within 28 days after randomization.
- 371 Use of life support was defined as the need for:
- Invasive mechanical ventilation: use of mechanical ventilation via a cuffed endotracheal
 tube.
- Circulatory support: infusion of any vasopressor/inotrope agent for a minimum of 1 hour (i.e.
 norepinephrine, epinephrine, phenylephrine, vasopressin analogues, angiotensin,
 dopamine, dobutamine, milrinone or levosimendan).
- Renal replacement therapy: any form of acute or chronic intermittent or continuous renal
 replacement therapy (RRT), including days between intermittent RRT. We defined periods
 with up to 3 days between intermittent RRT as days with RRT (e.g. if a patient received
 RRT on day 1, did not receive RRT on days 2-4, and received RRT again on day 5, the
 patient was considered on RRT on days 1-5).
- 382

383 Secondary outcome

- Number of patients with one or more serious adverse reactions (SARs) at day 28 was
 assessed as at least one of the following on each day from randomization to day 28:
- New episodes of septic shock: we defined septic shock according to the Sepsis-3
 criteria:²
- Suspected or confirmed superinfection.
- New infusion (or 50% increase) of vasopressor/inotropic agent (i.e.
 norepinephrine, epinephrine, phenylephrine, vasopressin analogues,
 angiotensin, dopamine, dobutamine, milrinone or levosimendan) to maintain a
 mean arterial blood pressure of 65 mmHg or above.
- Lactate of 2 mmol/L or above in any plasma sample performed on the same day
- Invasive fungal infection: any of the following:

395 Suspected invasive fungal infection: presence of plasma markers in blood (e.g. candida mannan antigen and galactomannan antigen). 396 Confirmed invasive fungal infection: positive culture from blood, peritoneal fluid 397 398 or tissue. Clinically important gastrointestinal (GI) bleeding was assessed as any GI bleeding 399 **AND** the use of at least 2 units of red blood cells on the same day. GI bleeding defined 400 as hematemesis, coffee ground emesis, melena, haematochezia or bloody nasogastric 401 402 aspirate on this day. Anaphylactic reaction to IV dexamethasone: anaphylactic reactions was only recorded 403 404 during the intervention period (i.e. for up to 10 days depending on the number of days 405 with corticosteroid use before randomization). An anaphylactic reactions was defined as 406 urticarial skin reaction AND at least one of the following observed after randomization Worsened circulation (>20% decrease in blood pressure or >20% increase in 407 408 vasopressor dose). Increased airway resistance (>20% increase in the peak pressure on the 409 ventilation) 410 Clinical stridor or bronchospasm. 411 _ Subsequent treatment with bronchodilators. 412 -413 2. All-cause mortality at day 28 after randomization: death from any cause within 28 days post-randomization. 414 415 The following secondary longer-term outcomes are also registered in the COVID STEROID 2 trial³ 416 but will be reported later when follow-up has completed. 417 418 1. All-cause mortality at day 90 after randomization. 2. Days alive without life support (i.e. invasive mechanical ventilation, circulatory support or 419 renal replacement therapy) at day 90. 420 3. Days alive and out of hospital at day 90. 421 422 4. All-cause mortality at 180 days after randomization. 5. Health-Related Quality of Life (HRQoL) at 180 days after randomization assessed by EQ-423

5D-5L.

424

425 6. Health-Related Quality of Life (HRQoL) at 180 days after randomization assessed by EQ426 VAS.

427 Criteria for Discontinuation of Trial Medication and Withdrawal

- 428
- The procedure for handling withdrawal of consent from a patient followed national regulations.

431 Discontinuation and withdrawal at the choice of the patient or the proxy

The patient or next of kin could withdraw his/her consent or proxy consent at any time without

433 further explanations and without consequences for further treatment. In these instances, the

- 434 investigator asked the patient or next of kin if they allowed continued data registration and follow-
- up until day 180. Already collected data up until the time of withdrawal were used according tonational regulations.
- If the patient was withdrawn before the first dose of trial medication was administered, the patient was not considered a part of the intention-to-treat (ITT) population. If the patient was withdrawn after one or more doses of trial medication were administered, and the patient or next of kin allowed continued data registration, the patient remained in the ITT population. If the patient was withdrawn after one or more doses of trial medication were administered, and the patient or next of kin withdrawn after one or more doses of trial medication were administered, and the patient or next of kin did not allow continued data registration, the patient remained in the ITT population but with missing data from the time of withdrawal. For patients withdrawn in Switzerland due to withdrawal
- of consent, all registered data were deleted, including the data registered before the time of
- withdrawal as required by the Swiss Ethics Committee. Any such Swiss patient was not part of theITT population.
- 447

448

449 Discontinuation and withdrawal at the choice of the investigator

- 450 A patient could have the intervention stopped by the clinician or investigator at any time if:
- The patient experienced intolerable adverse reactions or events (including SARs or suspected
- unexpected serious adverse reactions (SUSARs)) suspected to be related to the trialintervention.
- The clinicians in conjunction with the coordinating investigator decided it to be in the interest of
 the patient.
- The patient was withdrawn from active therapy.
- The patient was subject to compulsory hospitalisation.

458

In these patients, the collection of data and the follow-up continued, and the patient remained inthe ITT population.

461 **Trial Populations**

462

463 **Definition of the ITT population**

The ITT population was defined as all randomized patients and for whom there was consent for the use of data.

466

467 **Definition of the per-protocol population**

The per-protocol population was defined as the ITT population except those having one or more

469 major protocol violations during the intervention period (for up to 10 days depending on the number

470 of consecutive days with corticosteroid use before randomization) defined as:

- Use of open-label systemic corticosteroids.
- Trial medication not administered as per protocol (1 bolus injection of either 12 mg or 6 mg
- dexamethasone according to the allocation on each day during the intervention period).
- 474 Patients who discontinued trial medication due to withdrawal of consent or for clinical reasons were
- 475 considered as part of the per-protocol population.

476 Handling of Missing Data

477

478 **Complete missingness of data**

We had complete missingness of data for 5 patients who withdrew consent and had all registered
data deleted, including the data registered before the time of withdrawal as required by the Swiss
Ethics Committee.

482

483 Missing baseline variables

484 We had missing source data for the time from onset of symptoms to hospital admission for 32 485 patients allocated to dexamethasone 12 mg and for 18 patients allocated to dexamethasone 6 mg; 486 for the fraction of inspired oxygen for patients receiving invasive mechanical ventilation for 1 487 patient allocated to dexamethasone 12 mg; for the fraction of inspired oxygen for patients receiving 488 non-invasive ventilation or continuous use of CPAP for 4 patients allocated to dexamethasone 12 mg and for 8 patients allocated to dexamethasone 6 mg; for the most recent partial pressure of 489 oxygen (PaO2) prior to randomization for 28 patients allocated to dexamethasone 12 mg and for 490 23 patients allocated to dexamethasone 6 mg; for the most recent arterial oxygen saturation prior 491 492 to randomization for 5 patients allocated to dexamethasone 12 mg and for 9 patients allocated to dexamethasone 6 mg; and for the highest plasma lactate value in the last 24 hours prior to 493 494 randomization for 57 patients allocated to dexamethasone 12 mg and for 49 patients allocated to 495 dexamethasone 6 mg. The missing data in these patients were not included in the baseline 496 characteristics.

497

498 Missing outcome data

499 Primary outcome

500 We had data for the primary outcome for 971 of 982 (98.9%) patients in the ITT population (98.8% 501 in patients allocated to dexamethasone 12 mg; 99.0% in patients allocated to dexamethasone 6 502 mg). 11 patients had missing data due to withdrawal of consent from the time of withdrawal; no 503 patients were lost to follow-up.

504

506

507 Secondary outcomes

508 We had data for 28-day mortality for 971 of 982 (98.9%) patients in the ITT population (98.8% in

509 patients allocated to dexamethasone 12 mg; 99.0% in patients allocated to dexamethasone 6 mg).

510 11 patients had missing data due to withdrawal of consent from the time of withdrawal; no patients

511 were lost to follow-up.

512 We analyzed data for SARs for all 982 patients in the ITT population. For the 11 patients who

- 513 withdrew consent before 28-days follow up, the occurrence of serious adverse reactions was
- analyzed until the day of withdrawal of consent
- 515

516 Logical imputation

517 We used logical imputation for one patient that likely left the country of enrolment before 28-days

518 follow-up. The patient was last seen alive 3 days before 28-days follow up, where the patient was 519 assessed to be fit-to-fly by a medical doctor. Consequently, the patient was assumed to be alive,

520 without the need for life support, and without any serious adverse reactions after discharge and 521 until day 28 after randomization.

522 We used logical imputation for one patient for whom the relatives could inform that the patient had 523 received renal replacement therapy after discharge, but not the number of days with renal

replacement therapy after discharge. The patient died on day 46 after randomization. For this

525 patient, we assumed that the patient received renal replacement therapy (including days in

526 between intermittent renal replacement therapy) at all days from discharge to 28-days follow-up.

527

528

530 Abstract Written before Breaking the Randomization Code

v. 1.3, June 26, 2021, approved by the Management Committee

532 Background

533 Dexamethasone 6 mg daily is recommended for up to 10 days in patients with severe and critical

- 534 Covid-19. A higher dose of dexamethasone may benefit those with more severe disease.
- 535

536 Methods

In this international, blinded trial, we randomly assigned adults with confirmed Covid-19 receiving at least 10 L/min of oxygen or mechanical ventilation to intravenous dexamethasone 12 mg or dexamethasone 6 mg daily for up to 10 days. The primary outcome was the number of days alive without life support (i.e. invasive mechanical ventilation, circulatory support or renal replacement therapy) at 28 days.

542

543 Results

- We randomized 1000 patients, included 982 in the intention-to-treat-population and had primary
 outcome data for 971, among whom 491 patients were assigned to dexamethasone A mg and 480
 patients assigned to dexamethasone B mg. The median number of days alive without life support
 at 28 days was 22.0 days (interquartile range 6.0-28.0) in the A mg group and 20.5 days (4.0-28.0)
 in the B mg group (adjusted mean difference 1.3 days, 95% confidence interval (CI), 0.0-2.6;
 P=0.066). The 28-day mortality was 27.1% and 32.3% in patients assigned to A mg and B mg,
- respectively, (adjusted relative risk 0.86, 99% CI, 0.68-1.09). The 28-day occurrence of serious
- adverse reactions were similar in the two groups (adjusted relative risk 0.85, 99% CI, 0.56-1.31).
- 552

553 Conclusions

- Among patients with Covid-19 and severe hypoxia, dexamethasone A mg probably led to more
- 555 days alive without life support at 28 days than dexamethasone B mg.
- 556

557 Note, 28 June 2021. The upper confidence interval for 28-day mortality differs between the abstract written before 558 breaking the randomization code and the final one due to simulation uncertainty and rounding; these estimates were 559 calculated using logistic regression and g-computation, which involved a bootstrap resampling procedure to estimate 560 confidence intervals, with 5,000 samples used in the analyses conducted before unblinding and 50,000 samples used in 561 the final analyses.

562 Note, 21 July 2021. Four serious adverse reactions were refuted when reviewed before final reporting to institutional
 563 ethics committees. The adjusted relative risk therefore differs between the abstract written before breaking the
 564 randomization code and the final one.

565 **eFigures**

566

567 **eFigure 1. Masking of Trial Medication**

We used shelf-medications from the hospital department's pharmacy for the trial interventions. To ensure blinding, the trial medications were prepared by a team of unblinded trial staff; all others, including the patients and clinical staff, remained blinded to the treatment allocation. For each patient, the trial medication was be prepared once daily and administered as a bolus injection intravenously.


- 573 Dexamethasone phosphate (used at all hospitals expect in the one Swedish hospital where
- 574 bethamethasone phosphate was used) is a clear colourless solution. To ensure blinding, the
- 575 dexamethasone phosphate solution was mixed with isotonic saline (0.9%) to a bolus volume of 5
- 576 ml for both trial interventions. Consequently, the 12 mg and 6 mg dexamethasone bolus injections
- 577 appeared identical upon visual inspection (eFigure 1). The preparation of trial medication is
- 578 described in detail in the Supporting Information S5 in the primary protocol.³

COVID STEROID 2 trial medication for clinical trial Dexamethasone 12 mg OR dexamethasone 6 mg
For injection
Patient name
Identification number
Date and time of preparation of trial medication
Signature
Must be stored at ≤ 25 °C
Questions? Contact HOTLINE tel. +45 3545 7237
Sponsor: Prof. Anders Perner, Dept. of Intensive Care, Rigshospitalet, Denmark. Tel. +45 3545 8333

- 579
- 580 **eFigure 1. Masking of trial medication.** Trial interventions (12 mg and 6 mg of dexamethasone)
- 581 without labels (to the left). Both interventions were labelled with identical labels (to the right).
- 582
- 583
- 584

585	Local trade names
586	The local trade names used in the COVID STEROID 2 trial are listed below.
587	
588	<u>Denmark</u>
589	Dexavit™, Vital Pharma Nordic, Denmark, ATC code: H02AB02.
590	
591	Sweden
592	Betapred™, Alfasigma S.p.A., Italy, ATC code: H02AB01.
593	Dexavit™, Vital Pharma Nordic, Denmark, ATC code: H02AB02.
594	
595	Switzerland
596	Mephameson™, Mepha Pharma AG, Switzerland, ATC code: H02AB02.
597	
598	India
599	Daksone™, Daksh Pharmaceuticals Pvt. Ltd, India, ATC code: H02AB02.
600	Dacdac™, Wockhardt Limited (Merind), India, ATC code: H02AB02.
601	Decmax™, GLS Pharma Ltd., India, ATC code: H02AB02.
602	Demisone™, Cadila Pharmaceuticals Ltd. (Genvista), India, ATC code: H02AB02.
603	Dexona™, Zydus Cadila Healthcare Ltd. (Alidac), India, ATC code: H02AB02.
604	Dex-V™, Vensat Bio, India, ATC code: H02AB02.

605 Intradex™, Intra Labs India Pvt. Ltd, India, ATC code: H02AB02.




606 eFigure 2. Number of Enrolments per Site




The 4 sites at Rigshospitalet, Denmark, was run by one research staff team; so was the 3 sites at Hvidovre Hospital, Denmark.

- **eFigure 3. Number of Enrolments per Month**



- 623 eFigure 4. Distributions of the Primary Outcome in the Post Hoc Analyses of the Primary Outcome Assigning Patients
- 624 Who had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)





⁶²⁶

- eFigure 4 shows the number of days alive without life support as horizontally stacked proportions in the two intervention groups in the
- 628 intention-to-treat population in the post hoc analysis assigning patients who had died at day 28 the worst possible outcome of 0 days alive
- 629 without life support at day 28 after randomization (n=971; 11 patients had missing primary outcome data). Red represents worse
- 630 outcomes, and blue represents better outcomes.

631 eTables

632

eTable 1a and 1b. Randomizations in Error and Wrongly Entered Stratification

- 634 Variables
- 635

636 eTable 1a: Randomizations in error

Reason for randomization in error	Number of patients
Ineligible at the time of randomization ^a	8
Did not fulfill inclusion criteria ^b	4
Fulfilled one or more exclusion criteria ^c	4
Duplicate randomizations ^d	1

^a All 8 patients were included in the ITT population.

^b 3 patients received less than 10 L/min of supplementary oxygen and 1 was PCR-negative for SARS-CoV-2.

^c 3 had received corticosteroids for Covid-19 for 5 consecutive days or more, and 1 had an indication for systemic corticosteroids in a dose higher than dexamethasone 6 mg or equivalent.

^d The patient received trial medication according to the allocation at the first randomization and was only included once in the ITT population.

637

638 eTable 1b: Wrongly entered stratification variables

Stratification variable ^a	Number of patients
Site ^b	6
Invasive mechanical ventilation	7
Age below 70 years	18

^a The wrongly entered stratification variables were corrected for all these 31 patients before the adjusted analyses were conducted.

^b Some investigators had access to more than one site in the electronic case report form where screening was performed. As a result, 6 patients were administratively allocated at a wrong site.

639 eTable 2. Trial Medication Administration and Protocol Violations

640

	Dexamethasone 12 mg (n=497)	Dexamethasone 6 mg (n=485)
Trial medication administration		
Treatment duration, median (IQR), days	7 (5 - 9)	7 (6 - 9)
Major protocol violation, no. (%)	44 (8.9%)	46 (9.5%)
Use of open-label systemic corticosteroids	10 (2.0%)	9 (1.9%)
Trial medication not administered as per	·	
protocol	36 (7.2%)	39 (8.0%)

641 Abbreviations: mg, milligrams; IQR, interquartile range.

eTable 3. Results of the Analysis of the Primary Outcome in the Per Protocol 642

Population^a 643

644

Primary outcome	Dexamethasone	Dexamethasone	Mean	Median
	12 mg	6 mg	difference	difference
	(N=453)	(N=439)	(95% Cl) ^b	(95% CI) ^b
Number of days alive without life support, median (IQR) ^c	23.0 (6.0-28.0)	20.0 (4.0-28.0)	1.3 (0.0 to 2.7)	0 (-0.9 to 0.9)

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Defined as the ITT population except those having one or more major protocol violations (i.e. use of open-label systemic corticosteroids and/or trial medication not administered as per protocol) during the intervention period (N = 892).

^b Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence intervals for the final analysis. [°] Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive

mechanical ventilation, and age below 70 years).

eTable 4. Best-Worst/Worst-Best Case Analyses of the Primary Outcome 645 646

	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% Cl) ^a	Median difference (95% CI) ^a
Best-worst case analysis ^b				
Number of days alive without life support, median (IQR)	22.0 (6.0-28.0)	20.0 (4.0-28.0)	1.6 (0.3 to 2.9)	0 (-0.8 to 0.8)
Worst-best case analysis ^c				
Number of days alive without life support, median (IQR)	22.0 (5.0-28.0)	21.0 (4.0-28.0)	1.1 (-0.2 to 2.4)	0 (-0.5 to 0.5)

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence intervals for the final analysis. Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years).

Analyzed assuming all patients lost to follow-up in the 12 mg group have had a beneficial outcome (i.e. assuming that the patient was alive and without life support for all days with missing data) and all patients lost to follow-up in the 6 mg group have had a harmful outcome (i.e. assuming that the patient was dead and/or received life support on all days with missing data). ^c Analyzed assuming all patients lost to follow-up in the 12 mg group have had a harmful outcome

((i.e. assuming that the patient was dead and/or received life support on all days with missing data) and all patients lost to follow-up in the 6 mg group have had a beneficial outcome (i.e. assuming that the patient was alive and without life support for all days with missing data).

eTable 5. *Post Hoc* Analyses of the Primary Outcome Assigning Patients Who Had Died at Day 28 the Worst Possible Outcome (i.e., 0 Days Alive Without Life Support)

Outcome	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% CI) ^a	Median difference (95% CI) ^a
Primary outcome ^b				
Number of days alive without life support, median (IQR)	22 (0 - 28)	20 (0 - 28)	1.5 (0.1 to 3.0)	0 (-1.1 to 1.1)
Number of days alive without				
invasive mechanical ventilation,				
median (IQR)	23 (0 - 28)	21 (0 - 28)		
Number of days alive without circulatory support, median		· · ·		
(IQR)	26 (0 - 28)	25 (0 - 28)		
Number of days alive without renal replacement therapy, median (IQR) ^c	28 (0 - 28)	28 (0 - 28)		

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range. Before the lock of the trial database, we decided to do this *post hoc* sensitivity analysis assigning dead patients the worst possible outcome (i.e. 0 days alive without life support) as this as previously been proposed and is frequently used in other, similar trials.^{4,5}

^a Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years. Significance level is set to 5% including the interim analysis for the primary outcome. Accordingly, we have employed 95.08% confidence interval for the primary outcome.

^b Defined as days alive and without the use of invasive mechanical ventilation, circulatory support or renal replacement therapy. Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

^c Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

650 eTable 6. Analyses of the Single Components of Composite Outcomes

651

Outcomes at day 28	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)	Mean difference (95% CI) ^ª	Median difference (95% CI) ^ª
Primary outcome: days alive without life support ^b				
Number of days alive without invasive mechanical ventilation, median (IQR)	23 (7 - 28)	22 (5 - 28)	1.0 (-0.3 to 2.2)	0 (-0.5 to 0.5)
Number of days alive without circulatory support, median (IQR)	26 (13 - 28)	25 (9 - 28)	1.0 (-0.2 to 2.2)	0 (-0.1 to 0.1)
Number of days alive without renal replacement therapy, median (IQR) ^c	28 (18 - 28)	28 (14 - 28)	0.7 (-0.4 to 1.8)	_d
Secondary outcome: serious adverse reactions, no. (%) ^e			Relative risk (99% CI) ^a	Risk difference (99% CI) ^a
New episodes of septic shock	42 (8.5%)	49 (10.1%)	0.85 (0.50 to 1.43)	-1.5 (-6.2 to 3.2)
Invasive fungal infection	15 (3.0%)	21 (4.3%)	0.70 (0.27 to 1.64)	-1.3 (-4.2 to 1.7)
Clinically important gastrointestinal bleeding	9 (1.8%)	5 (1.0%)	_t ^	_t _
Anaphylactic reaction to intravenous dexamethasone ^g	0 (0.0%)	0 (0.0%)	-	-

Abbreviations: mg, milligrams; CI, confidence interval; IQR, interquartile range.

^a Significance level is set to 5% including the interim analysis. Accordingly, we have employed 95.08% confidence interval for the primary outcome, and 99% confidence intervals for the secondary outcomes. Risk differences are reported in percentage points.

^b Analyzed using the Kryger Jensen and Lange test adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years). Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

^c Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

^d Not applicable as too many observations are identical.

^e Analyzed using logistic regression and g-computation adjusted for the stratification variables (site, invasive mechanical ventilation, and age below 70 years).

^f Too few events to be meaningfully analyzed.

^g Only recorded during the intervention period (for up to 10 days).

eTable 7. Results of the Unadjusted Analyses of Secondary Outcomes

Secondary outcomes ^a	Relative risk (99% CI)	Risk difference (99% Cl)
Death by day 28	0.84 (0.65 to 1.08)	-5.2 (-12.7 to 2.3)
Patients with one or more serious adverse reactions ^b	0.85 (0.61 to 1.19)	-1.9 (-6.1 to 2.2)

Abbreviations: CI, confidence interval.

^a Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg. Both outcomes are analyzed using generalized linear models with log/identity links and binomial error distributions. Risk differences are reported in percentage points. ^b Defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal

² Defined as new episodes of septic shock, invasive fungal infection, clinically important gastrointestin bleeding or anaphylactic reaction to intravenous dexamethasone.

eTable 8. All Serious Adverse Reactions and Serious Adverse Events^a 654 655

	Dexamethasone 12 mg (N=497)	Dexamethasone 6 mg (N=485)
SARs registered in addition to those in the SAR- outcome, no. (%) ^b		
Sepsis	2 (0.4%)	5 (1.0%)
Bacteraemia	4 (0.8%)	1 (0.2%)
Pneumonia	6 (1.2%)	7 (1.4%)
C. difficile	0 (0.0%)	1 (0.2%)
Other	3 (0.6%)	3 (0.6%)
Total ^c	14 (2.8%)	17 (3.5%)
SAEs, no. (%) ^d		
Thromboembolic events	4 (0.8%)	10 (2.1%)
Bleeding	7 (1.4%)	7 (1.4%)
Acute kidney injury	52 (10.5%)	62 (12.8%)
Pulmonary complications, including pneumothorax	3 (0.6%)	3 (0.6%)
Circulatory failure, including cardiac arrest	9 (1.8%)	9 (1.9%)
Other	7 (1.4%)	3 (0.6%)
Total ^e	70 (14.1%)	85 (17.5%)
Patients with one or more SARs or SAEs, no. (%) ^t	108 (21.7%)	130 (26.8%)

Abbreviations: mg, milligrams; SAE, serious adverse event; SAR, serious adverse reaction.

^a SAE and any SAR (both those included in the SAR-outcome (i.e. new episodes of septic shock, invasive fungal infection, clinically important gastrointestinal bleeding, or anaphylactic reaction to intravenous dexamethasone) and those reported directly to Sponsor or his delegate by e-mail or using a standardized report form). ^b Other registered SARs, i.e. adverse reactions registered in the Summary Product Characteristic for

dexamethasone considered serious and not registered in the secondary SAR outcome.

^c Total number of patients with at least one SAR not included in the secondary SAR outcome. ^d Any SAE not considered a SAR.

^e Total number of patients with at least one SAE.

^f Including the reactions reported in the secondary SAR outcome.

eTable 9. Use of Extracorporeal Membrane Oxygenation within 28 Days of 658 Randomization^a 659

660

	Dexamethasone 12 mg	Dexamethasone 6 mg
Extracorporeal membrane oxygenation, no. (%)	3 (0.6%)	14 (2.9%)

Abbreviations: mg, milligrams. ^a Data were missing for 6 patients assigned to dexamethasone 12 mg and 5 patients assigned to dexamethasone 6 mg.

eTable 10. Discharge Against Medical Advice within 28 Days of Randomization 661 662

	Dexamethasone 12 mg	Dexamethasone 6 mg
Discharged against medical advice, no. (%)	9 (1.8%)	11 (2.3%)
Use of life support at the time of discharge	1 (0.2%)	1 (0.2%)
Invasive mechanical ventilation	1 (0.2%)	1 (0.2%)
Circulatory support	0 (0.0 %)	0 (0.0 %)
Renal replacement therapy ^a	0 (0.0 %)	0 (0.0 %)
Use of supplementary oxygen at the time of		
discharge	5 (1.0%)	8 (1.7%)
≥ 10 l/min	2 (0.4%)	3 (0.6%)
0-9 l/min	3 (0.6%)	5 (1.0%)

Abbreviations: mg, milligrams; I, liters; min, minutes. ^a Any form of acute or chronic intermittent or continuous renal replacement therapy, including days between intermittent dialysis (i.e. we have considered up to 3 days in between renal replacement therapy as days with renal placement therapy).

663 eReferences

- Munch MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with
 COVID-19 and severe hypoxia: the COVID STEROID randomised, placebo-controlled trial.
 Acta Anaesthesiol Scand. 2021.
- Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus
 Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-810.
- Munch MW, Granholm A, Myatra SN, et al. Higher vs lower doses of dexamethasone in
 patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and
 statistical analysis plan. *Acta Anaesthesiol Scand.* 2021;65(6):834-845.
- 4. Schoenfeld DA, Bernard GR, Network A. Statistical evaluation of ventilator-free days as an
 efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. *Crit Care Med.* 2002;30(8):1772-1777.
- 6755.Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ676Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid
- Domain Randomized Clinical Trial. *JAMA*. 2020;324(13):1317-1329.